Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma.
H. Okada
No relevant relationships to disclose
P. Kalinski
No relevant relationships to disclose
A. H. Mintz
No relevant relationships to disclose
J. A. Engh
No relevant relationships to disclose
L. H. Butterfield
No relevant relationships to disclose
R. H. Hamilton
No relevant relationships to disclose
D. M. Potter
No relevant relationships to disclose
A. M. Salazar
Employment or Leadership Position - Oncovir (U)
F. S. Lieberman
No relevant relationships to disclose